摘要
目的:比较西格列汀和阿卡波糖治疗初发2型糖尿病(T2DM)的有效性与耐受性。方法:将60名患者随机分为西格列汀组(30例)和阿卡波糖组(30例),分别口服西格列汀100 mg,1次/日,阿卡波糖50 mg,3次/日。观察治疗前及治疗12周后患者空腹血糖(FPG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)及体重指数(BMI)的变化。结果:两组治疗后FPG、2hPG、HbA1c较治疗前均明显下降,差异有统计学意义(P<0.05)。西格列汀组治疗后FPG、HbA1c降低较阿卡波糖组明显,差异有统计学意义(P<0.05),餐后血糖两组间差异无统计学意义(P>0.05)。两组BMI变化无统计学意义(P>0.05)。阿卡波糖组不良反应比西格列汀组多。结论:西格列汀和阿卡波糖均可有效改善初发2型糖尿病患者的FPG、2hPG及HbA1c。西格列汀降低FPG、HbA1c的作用优于阿卡波糖,对餐后血糖的降低程度相似。
Objective:To explore the efficacy and tolerability of sitagliptin and acarbose on newly-diagnosed type 2 diabetes.Methods:60 cases were randomized divided into the sitagliptin group(30 cases) and the acarbose group(30 cases).Two groups were treated respectively with sitagliptin 100 mg,1 time/day,and acarbose 50 mg,3 times/day.We observed the changes of fasting blood glucose(FPG),2 hour postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c) and body weight before treatment and after 12 weeks of treatment.Results: The FPG,2hPG and HbA1 c after treatment obviously decreased,and the difference was statistically significant(P<0.05).After treatment,the decrease of FPG and HbA1 c of the sitagliptin group was more than those of the acarbose group,and the difference was statistically significant(P<0.05).The difference of 2hPG of the two groups after treatment was not statistically significant(P>0.05).Weight changes in the two groups were not statistically significant(P>0.05).Conclusion:Sitagliptin and acarbose can effectively improve the FPG,2hPG and HbA1 c of newly-diagnosed type 2 diabetes.The effect of reducing FPG and HbA1 c of sitagliptin is better than that of acarbose.The degree is similar to reduce the postprandial blood glucose.
